Revolution Medicines is the lead sponsor of 17 current clinical trials in our USA, UK, Ireland, China and EU (CTIS) registers. 13 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Cetuximab, Gemcitabine and Nab-paclitaxel. The most-studied condition is PDAC.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC
|
Phase 3 | Recruiting | 2025-05 | Ireland, UK, USA |
|
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma
|
Phase 1/2 | Recruiting | 2024-05 | USA |
|
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Drug: RMC-6236 |
Phase 1/2 | Recruiting | 2022-05 | USA |
|
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Drug: Cetuximab |
Phase 3 | Recruiting | 2025-12 | UK, USA |
|
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
NCT07805954 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
|
Phase 3 | Recruiting | 2026-08 | USA |
|
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
|
Phase 3 | Recruiting | 2026-05 | USA |
|
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
|
Phase 3 | Recruiting | 2026-03 | UK, USA, China |
|
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer
|
Phase 1/2 | Recruiting | 2024-01 | USA |
|
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822 · ClinicalTrials.gov ↗ · NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC
|
Phase 3 | Recruiting | 2026-08 | USA |
|
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1 | Recruiting | 2023-09 | USA |
|
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC)
|
Phase 1/2 | Recruiting | 2026-01 | USA |
|
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Drugs: Cetuximab, Elironrasib |
Phase 1/2 | Recruiting | 2023-11 | USA |
|
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma
Drug: Cetuximab |
Phase 1 | Recruiting | 2026-01 | USA |
|
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma
Drug: RMC-6291 |
Phase 1 | Active, closed | 2022-09 | USA |
|
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
|
Phase 3 | Active, closed | 2024-10 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Revolution Medicines as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
2025-524623-50-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Ongoing | Ireland + 8 more |
|
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
2025-524928-21-00 · Neoplasms
Drug: RMC-9805 |
Phase 3 | Authorised | Sweden, Spain, France + 9 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 15 | 13 |
| Clinical trials in UK | 3 | 3 |
| Clinical trials in Ireland | 1 | 1 |
| Clinical trials in China | 1 | 1 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Genfleet Therapeutics (Shanghai) | 2 |
| Immuneering Corporation | 1 |
| Tango Therapeutics | 1 |
| InxMed (Shanghai) | 1 |
Sponsors with the most current trials registered for this condition.
Revolution Medicines is the lead sponsor of 15 current trials on ClinicalTrials.gov in our USA, UK, Ireland and China registers, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 13 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 22 drugs and biologicals as interventions. The most frequent are Cetuximab (9), Gemcitabine (5), Nab-paclitaxel (5), RMC-6236 (5) and RMC-9805 (5). The number in brackets is how many of its trials name each drug.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.